Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia

Abstract

Treatment options for chronic lymphocytic leukemia, the most common leukemia in the United States, have expanded rapidly in recent years. While traditional chemoimmunotherapy still remains a mainstay for young, fit patients, a number of novel targeted therapies have emerged that have changed the therapeutic landscape. Two innovative anti-CD20 monoclonal antibodies, obinutuzumab and ofatumomamab, have demonstrated activity in chronic lymphocytic leukemia and represent well-tolerated options in upfront management of elderly patients or in those with significant comorbidities. Agents targeting the B-cell receptor pathway, ibrutinib and idelalisib, have excellent activity in chronic lymphocytic leukemia, particularly in those patients with 17p deletions, in which responses to chemoimmunotherapy are traditionally dismal. Venetoclax (ABT-199), the recently FDA-approved BCL2 inhibitor, as well as several other agents and therapy combinations in the pipeline offer great promise for patients with chronic lymphocytic leukemia, particularly in the relapsed/refractory setting. This article comprehensively reviews the data for novel agents in chronic lymphocytic leukemia, including the pharmacology of therapies, unique toxicities, and other practical management considerations for clinicians.

Keywords

Chronic lymphocytic leukemia ibrutinib idelalisib monoclonal antibodies venetoclax

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Jemal

. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29.

SEER Cancer Statistics Factsheets: Chronic lymphocytic leukemia. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/statfacts/html/clyl.html (2015, accessed 23 January 2016).

Gale

Cozen

Goodman

et al.

Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 2000; 24: 665–669.

Pan

JWY

Cook

Schwartz

et al.

Incidence of leukemia in Asian migrants to the United States and their descendants. Cancer Causes Control 2002; 13: 791–795.

Döhner

Stilgenbauer

Benner

et al.

Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

Rossi

Rasi

Fabbri

et al.

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521–529.

Oscier

Rose-Zerilli

MJJ

Winkelmann

et al.

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121: 468–475.

Rossi

Fangazio

Rasi

et al.

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119: 2854–2862.

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Non Hodgkin’s Lymphomas Version 1.2016. Washington, PA: National Comprehensive Cancer Network.

10.

Cramer

Hallek

. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol 2011; 8: 38–47.

11.

US Food and Drug Administration. Center for drug evaluation and research, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125486Orig1s000CDTL.pdf (2013, accessed January 14 2016).

12.

Hallek

Fischer

Fingerle-Rowson

et al.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (London, England) 2010; 376: 1164–1174.

13.

Fischer

Bahlo

Fink

et al.

Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127: 208–215.

14.

Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). In: ASH 2014, San Francisco, CA, Abstract 19, 2004. Washington, DC: ASH.

15.

Hillmen

Robak

Janssens

et al.

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet (London, England) 2015; 385: 1873–1883.

16.

Goede

Fischer

Busch

et al.

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101–1110.

17.

Goede V, Fischer K, Bosch F, et al. Updated survival analysis from the CLL11 study: Obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia. In: ASH 2015, Orlando, FL, Abstract 1733, 2015. Washington, DC: ASH.

18.

Byrd

Furman

Coutre

et al.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.

19.

Byrd

Furman

Coutre

et al.

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497–2506.

20.

Byrd

Brown

O’Brien

et al.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.

21.

Furman

Sharman

Coutre

et al.

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997–1007.

22.

Roberts

Davids

Pagel

et al.

Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 311–322.

23.

Tam

O’Brien

Wierda

et al.

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980.

24.

Thompson

Tam

O’Brien

et al.

Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303–309.

25.

Rossi

Terzi-di-Bergamo

De Paoli

et al.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 2015; 126: 1921–1924.

26.

Teeling

Mackus

WJM

Wiegman

LJJM

et al.

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177: 362–371.

27.

Wierda

Kipps

Mayer

et al.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749–1755.

28.

Huang H, Li XY, Li HR, et al. Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: A prospective study to compare entecavir and lamivudine. In: ASCO 2013, Chicago, IL, Abstract 8503, 2013. Alexandria, VA: ASCO.

29.

Lim

Vaughan

Ashton-Key

et al.

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118: 2530–2540.

30.

Gagez

A-L

Cartron

. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol 2014; 26: 484–491.

31.

Alduaij

Ivanov

Honeychurch

et al.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117: 4519–4529.

32.

Shah

. New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab. Ther Clin Risk Manag 2015; 11: 1113–1122.

33.

Burger

Chiorazzi

. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592–601.

34.

Kraus

Alimzhanov

Rajewsky

et al.

Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004; 117: 787–800.

35.

Scupoli

Pizzolo

. Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. Expert Rev Hematol 2012; 5: 341–348.

36.

Stevenson

Krysov

Davies

et al.

B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313–4320.

37.

de Gorter

DJJ

Beuling

Kersseboom

et al.

Bruton’s tyrosine kinase and phospholipase Cγ2 mediate chemokine-controlled B cell migration and homing. Immunity 2007; 26: 93–104.

38.

Spaargaren

Beuling

Rurup

et al.

The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 2003; 198: 1539–1550.

39.

Herman

SEM

Gordon

Hertlein

et al.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287–6296.

40.

Berglöf

Hamasy

Meinke

et al.

Targets for ibrutinib beyond B cell malignancies. Scand J Immunol 2015; 82: 208–217.

41.

Brown

Hillmen

O'Brien

et al.

Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2014, San Francisco, CA, Abstract 3331,– 2014. Washington, DC: ASH.

42.

Farooqui

MZH

Valdez

Martyr

et al.

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015; 16: 169–176.

43.

McMullen

Boey

EJH

Ooi

JYY

et al.

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014; 124: 3829–3830.

44.

McMullen

Amirahmadi

Woodcock

et al.

Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 2007; 104: 612–617.

45.

Byrd

Hillmen

James

. Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. Blood 2015; 125: 1673–1673.

46.

Kamel

Horton

Ysebaert

et al.

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015; 29: 783–787.

47.

Quek

Bolen

Watson

. A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998; 8: 1137–1140.

48.

Imbruvica [package insert]. Sunnyvale, CA: Pharmacyclics. Last revised January 2015. Available at: https://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing_information.pdf.

49.

Jones JA, Hillmen P, Coutre S, et al. Pattern of use of anticoagulation and/or antiplatelet agents in patients with chronic lymphocytic leukemia (CLL) treated with single-agent ibrutinib therapy. In: ASH 2014, San Francisco, CA, Abstract 1990, 2014. Washington, DC: ASH.

50.

Clayton

Bardi

Bell

et al.

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002; 196: 753–763.

51.

Vanhaesebroeck

Welham

Kotani

et al.

P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997; 94: 4330–4335.

52.

Okkenhaug

Vanhaesebroeck

. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003; 3: 317–330.

53.

Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. In: ASH 2014, Abstract 330, 2014.

54.

Coutre S, Barrientos JC, Brown J, et al. Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. In: ASCO 2015, Chicago, IL, Abstract e18030. Alexandria, VA: ASCO.

55.

Coutré

Barrientos

Brown

et al.

Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 2015; 56: 2779–2786.

56.

Zydelig [package insert]. Foster City, CA: Gilead Sciences. Last revised July 2014. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf.

57.

Woyach

Smucker

Smith

et al.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014; 123: 1810–1817.

58.

Herman

SEM

Niemann

Farooqui

et al.

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28: 2188–2196.

59.

Fiorcari

Brown

McIntyre

et al.

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One 2013; 8: e83830–e83830.

60.

Brown

Barrientos

Barr

et al.

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 2015; 125: 2915–2922.

61.

Jaglowski

Jones

Nagar

et al.

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood 2015; 126: 842–850.

62.

Burger

Keating

Wierda

et al.

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014; 15: 1090–1099.

63.

Brown

Byrd

Coutre

et al.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390–3397.

64.

Maffei

Fiorcari

Martinelli

et al.

Targeting neoplastic B cells and harnessing microenvironment: the ‘double face’ of ibrutinib and idelalisib. J Hematol Oncol 2015; 8: 60–60.

65.

Herman

SEM

Mustafa

Jones

et al.

Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res 2015; 21: 4642–4651.

66.

Hallek

Cheson

Catovsky

et al.

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.

67.

Hotchkiss

Strasser

McDunn

et al.

Cell death. N Engl J Med 2009; 361: 1570–1583.

68.

Anderson

Huang

Roberts

. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014; 51: 219–227.

69.

Czabotar

Lessene

Strasser

et al.

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49–63.

70.

Chipuk

Green

. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008; 18: 157–164.

71.

Llambi

Moldoveanu

Tait

SWG

et al.

A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517–531.

72.

Tse

Shoemaker

Adickes

et al.

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421–3428.

73.

Roberts

Seymour

Brown

et al.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488–496.

74.

Zhang

Nimmer

Tahir

et al.

Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14: 943–951.

75.

Venclexta [package insert]. North Chicago, IL: AbbVie, Inc. Last revised April 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf.

76.

Thompson

O’Brien

Wierda

et al.

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 2015; 121: 3612–3621.

77.

Maddocks

Ruppert

Lozanski

et al.

Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 2015; 1: 80–87.

78.

Parikh SA, Chaffee KR, Call TG, et al. Ibrutinib therapy for chronic lymphocytic leukemia (CLL): An analysis of a large cohort of patients treated in routine clinical practice. In: ASH 2015, Orlando, FL, Abstract 2935, 2015. Washington, DC: ASH.

79.

Sandoval-Sus JD, Chavez JC, Dalia S, et al. Outcomes of patients with relapsed/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience. In: ASH 2015, Orlando, FL, Abstract 2945, 2015. Washington, DC: ASH.

80.

Barrientos JC, Kaur M, Mark A, et al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after idelalisib therapy discontinuation. In: ASH 2015, Orlando, FL, Abstract 4155, 2015. Washington, DC: ASH.

81.

Woyach

Johnson

. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood 2015; 126: 471–477.

82.

Fresquet

Rieger

Carolis

et al.

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 2014; 123: 4111–4119.

83.

Skarzynski

Niemann

Lee

et al.

Interactions between ibrutinib and anti-CD20 antibodies: Competing effects on the outcome of combination therapy. Clin Cancer Res 2016; 22: 86–95.